Good to see that the UK remains an attractive place for making medicines thanks to our skilled workforce, low tax rates and our countries leading position in life sciences. GlaxoSmithKline plan to invest £275 million at 3 drug manufacturing sites
- Barnard Castle in County Durham will receive £92m to fund the construction of an aseptic sterile facility.
- Montrose in Angus in Scotland will get £110 million for a new, state-of-the-art facility for the manufacture of respiratory active ingredients.
- Ware in Hertfordshire will receive £74 million for additional manufacturing capacity at the site.
GSK had argued against Brexit before the referendum and this investment shows a true vote of confidence in Britain that there is no better place to grow our biotech sector.
GlaxoSmithKline (GSK.L) plans 275 million pounds of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union.